Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study)
This study has been completed.
Information provided by (Responsible Party):
First received: June 22, 2012
Last updated: May 23, 2017
Last verified: May 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||April 2016|
|Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||May 4, 2016|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, Selmaj KW; RADIANCE Study Group.. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Apr;15(4):373-81. doi: 10.1016/S1474-4422(16)00018-1. Epub 2016 Feb 12.